Biogen Advances New Alzheimer’s Drug to Final Stage Despite Mixed Data
Biogen has announced its progress in developing an experimental drug for Alzheimer’s disease, moving to the final stage of clinical trials despite previous disappointing results. The data suggests that the treatment reduces tau protein levels and slows cognitive decline.